46 results
8-K
EX-14.1
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
funds or assets.
Environmental Matters
The Company is committed to operating its business in a manner that protects the environment as much … as possible, and is further committed to compliance with all applicable environmental laws, regulations, and industry best practices, such as those
S-4/A
4fxr9
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4/A
EX-10.35
qqq twh54
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
xgaknm
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
oxrh5r02nno4xy
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
lga mjbc0fj1qj
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am
8-K
EX-1.1
z6tyfipydph5 qw25qq5
4 Nov 21
Entry into a Material Definitive Agreement
4:58pm
8-K
EX-1.1
rgxd gx3p7k0ve5
2 Jul 20
Announces Pricing of $76.2 Million Public Offering
4:09pm